Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

RCT (n=357) found secondary cytoreduction followed by chemotherapy (CT) was linked to significantly longer progression-free survival than CT alone (17.4 vs 11.9 mths; HR 0.58;95%CI 0.45–0.74;p<0.0001) & advice patients should be counselled about this option in specialised centres

Source:

The Lancet Oncology